Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®.

Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Pia Sormani M, Ghezzi A.

Neurol Ther. 2018 Dec;7(2):391-393. doi: 10.1007/s40120-018-0116-x. Epub 2018 Nov 10. No abstract available.

2.

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.

J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.

PMID:
30259178
3.

Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP; ; On behalf of the iMUST Group.

Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390. [Epub ahead of print]

PMID:
30044207
4.

Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.

Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, Cavarretta R, Mantero V, Costantini G, D'Ambrosio V, Zaffaroni M, Ghezzi A, Perini P, Rossi S, Bertolotto A, Rottoli MR, Rovaris M, Balgera R, Cavalla P, Montomoli C, Bergamaschi R.

J Neurol. 2018 Aug;265(8):1850-1859. doi: 10.1007/s00415-018-8916-6. Epub 2018 Jun 14.

PMID:
29948245
5.

Clinical activity after fingolimod cessation: disease reactivation or rebound?

Frau J, Sormani MP, Signori A, Realmuto S, Baroncini D, Annovazzi P, Signoriello E, Maniscalco GT, La Gioia S, Cordioli C, Frigeni B, Rasia S, Fenu G, Grasso R, Sartori A, Lanzillo R, Stromillo ML, Rossi S, Forci B, Cocco E; i-MuST study group.

Eur J Neurol. 2018 Oct;25(10):1270-1275. doi: 10.1111/ene.13694. Epub 2018 Jul 10.

PMID:
29851435
6.

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.

J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.

PMID:
29549468
7.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
8.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
9.

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Novelli F, Durelli L, Clerico M.

J Neuroimmunol. 2017 Dec 15;313:89-91. doi: 10.1016/j.jneuroim.2017.10.009. Epub 2017 Oct 17.

10.

Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.

Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group.

Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1.

PMID:
29093064
11.

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal.

Novi G, Ghezzi A, Pizzorno M, Lapucci C, Bandini F, Annovazzi P, Mancardi GL, Uccelli A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jul 27;4(5):e377. doi: 10.1212/NXI.0000000000000377. eCollection 2017 Sep. No abstract available. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2018 Apr 12;5(3):e462.

12.

A Comprehensive Review on Copemyl®.

Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Sormani MP, Ghezzi A.

Neurol Ther. 2017 Dec;6(2):161-173. doi: 10.1007/s40120-017-0079-3. Epub 2017 Jul 31. Review.

13.

Hypomagnesaemia as a trigger of relapsing non-alcoholic Wernicke encephalopathy: a case report.

Baroncini D, Annovazzi P, Minonzio G, Franzetti I, Zaffaroni M.

Neurol Sci. 2017 Nov;38(11):2069-2071. doi: 10.1007/s10072-017-3062-y. Epub 2017 Jul 20. No abstract available.

PMID:
28730572
14.

History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.

Benoit A, Durand-Dubief F, Amato MP, Portaccio E, Casey R, Roggerone S, Androdias G, Gignoux L, Ionescu I, Marrosu MG, Cocco E, Ghezzi A, Annovazzi P, Trojano M, Simone M, Marignier R, Confavreux C, Vukusic S.

Neurology. 2016 Sep 27;87(13):1360-7. doi: 10.1212/WNL.0000000000003036. Epub 2016 Jul 27.

PMID:
27466470
15.

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.

Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, Centonze D, Perini P, Tortorella C, Prosperini L, Lus G, Fuiani A, Falcini M, Martinelli V, Comi G, Ghezzi A.

J Neurol. 2016 Sep;263(9):1727-35. doi: 10.1007/s00415-016-8188-y. Epub 2016 Jun 10.

PMID:
27286847
16.

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.

Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G.

Mult Scler. 2016 Sep;22(10):1315-26. doi: 10.1177/1352458516650736. Epub 2016 May 26.

PMID:
27230789
17.

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2016 Aug;3(4):e273.

18.

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A.

Mult Scler. 2015 Nov;21(13):1713-22. doi: 10.1177/1352458515570768. Epub 2015 Feb 19.

PMID:
25698174
19.

Uhthoff's phenomena and brain MRI suggesting demyelinating lesions: RIS or CIS? A case report.

Baroncini D, Zaffaroni M, Minonzio G, Annovazzi P, Baldini SM, Comi G, Ghezzi A.

J Neurol Sci. 2014 Oct 15;345(1-2):262-4. doi: 10.1016/j.jns.2014.07.020. Epub 2014 Jul 16. No abstract available.

PMID:
25064443
20.

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.

Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, Nociti V, D'Onghia M, Lo Re V, Rodegher M, Solaro C, Gasperini C.

Mult Scler. 2014 Aug;20(9):1265-8. doi: 10.1177/1352458514521311. Epub 2014 Feb 10.

PMID:
24515732
21.

Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis.

Guaschino C, Esposito F, Liberatore G, Colombo B, Annovazzi P, D'Amico E, Cavalla P, Capello E, Capra R, Galimberti D, Tedeschi G, Grimaldi L; PROGRESSO Group; PROGEMUS Group, Leone M, D'Alfonso S, Martinelli V, Comi G, Martinelli-Boneschi F.

Neurol Sci. 2014 May;35(5):789-91. doi: 10.1007/s10072-014-1650-7. Epub 2014 Feb 11.

PMID:
24514917
22.

Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.

Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP.

Expert Rev Clin Immunol. 2013 Jul;9(7):683-91; quiz 692. doi: 10.1586/1744666X.2013.811046. Review.

PMID:
23899239
23.

Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire).

Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, Giannini M, Patti F, D'Amico E, Frau J, Lorefice L, Bonavita S, Della Corte M, Grasso MG, Finamore L, Ghezzi A, Annovazzi P, Rottoli M, Gasperini C, Restivo D, Maimone D, Rossi P, Stromillo ML, Bergamaschi R.

J Neurol Sci. 2013 Aug 15;331(1-2):94-7. doi: 10.1016/j.jns.2013.05.020. Epub 2013 Jun 6.

PMID:
23747002
24.

Response competition and response inhibition during different choice-discrimination tasks: evidence from ERP measured inside MRI scanner.

Gonzalez-Rosa JJ, Inuggi A, Blasi V, Cursi M, Annovazzi P, Comi G, Falini A, Leocani L.

Int J Psychophysiol. 2013 Jul;89(1):37-47. doi: 10.1016/j.ijpsycho.2013.04.021. Epub 2013 May 9.

PMID:
23664841
25.

Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis.

Ghezzi A, Annovazzi P, Amato MP, Capello E, Cavalla P, Cocco E, Falcini M, Gallo A, Patti F, Perini P, Rodegher ME, Rovaris M, Rottoli MR, Comi G; MS Study Group-Italian Society of Neurology.

Mult Scler. 2013 Jun;19(7):961-3. doi: 10.1177/1352458513475491. Epub 2013 Feb 4.

PMID:
23380649
26.

Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases.

Ghezzi A, Annovazzi P, Cocco E, Coarelli G, Lugaresi A, Rovaris M, Patti F, Capello E, Rodegher ME, Moiola L, Malucchi S, Salemi G, De Rossi N, Provinciali L, Perini P, Bergamaschi R, Scarpini E, Lus G, Gallo A, Tola MR, Amato MP, Rottoli MR, Bianchi A, Comi G; MS Study Group-Italian Society of Neurology.

Neurol Sci. 2013 Sep;34(9):1633-7. doi: 10.1007/s10072-013-1300-5. Epub 2013 Jan 25.

PMID:
23354606
27.

Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

Ghezzi A, Rocca MA, Baroncini D, Annovazzi P, Zaffaroni M, Minonzio G, Comi G, Filippi M.

J Neurol. 2013 Jan;260(1):327-9. doi: 10.1007/s00415-012-6744-7. Epub 2012 Nov 16. No abstract available.

PMID:
23161460
28.

A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

Annovazzi P, Tomassini V, Bodini B, Boffa L, Calabrese M, Cocco E, Cordioli C, De Luca G, Frisullo G, Gallo A, Malucchi S, Paolicelli D, Pesci I, Radaelli M, Ragonese P, Roccatagliata L, Tortorella C, Vercellino M, Zipoli V, Gasperini C, Rodegher M, Solaro C.

Neurol Sci. 2013 Feb;34(2):197-203. doi: 10.1007/s10072-012-0981-5. Epub 2012 Mar 11.

PMID:
22407022
29.

Delayed diagnosis in pediatric headache: an outpatient Italian survey.

Colombo B, Dalla Libera D, De Feo D, Pavan G, Annovazzi PO, Comi G.

Headache. 2011 Sep;51(8):1267-73. doi: 10.1111/j.1526-4610.2011.01976.x.

PMID:
21884081
30.

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study.

Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M, Vitello G, Grimaldi LM, Ghezzi A, Martinelli V, Comi G.

Neurol Sci. 2011 Jan;31 Suppl 3:299-302. doi: 10.1007/s10072-010-0344-z.

PMID:
20544247
31.

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.

Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, Scotti R, Falini A, Sormani MP, Comi G, Filippi M.

Neurology. 2009 Dec 1;73(22):1842-8. doi: 10.1212/WNL.0b013e3181c3fd5b.

PMID:
19949030
32.

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.

Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group.

Neurol Sci. 2009 Jun;30(3):193-9. doi: 10.1007/s10072-009-0083-1. Epub 2009 Apr 22.

PMID:
19387545
33.

Headache therapy with neuronal stabilising drugs.

Colombo B, Dalla Libera D, Annovazzi PO, Comi G.

Neurol Sci. 2008 May;29 Suppl 1:S131-6. doi: 10.1007/s10072-008-0904-7. Review.

PMID:
18545914
34.

Lifetime and actual prevalence of pain and headache in multiple sclerosis.

Martinelli Boneschi F, Colombo B, Annovazzi P, Martinelli V, Bernasconi L, Solaro C, Comi G.

Mult Scler. 2008 May;14(4):514-21. doi: 10.1177/1352458507085551.

PMID:
18562506
35.

Impaired short-term motor learning in multiple sclerosis: evidence from virtual reality.

Leocani L, Comi E, Annovazzi P, Rovaris M, Rossi P, Cursi M, Comola M, Martinelli V, Comi G.

Neurorehabil Neural Repair. 2007 May-Jun;21(3):273-8. Epub 2007 Mar 9.

PMID:
17351084
36.

Medications for neuropathic pain: current trends.

Colombo B, Annovazzi PO, Comi G.

Neurol Sci. 2006 May;27 Suppl 2:S183-9. Review.

PMID:
16688627
37.

Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis.

Tortorella P, Rocca MA, Colombo B, Annovazzi P, Comi G, Filippi M.

J Neurol Sci. 2006 May 15;244(1-2):137-41. Epub 2006 Mar 13.

PMID:
16530789
38.

Movement preparation is affected by tissue damage in multiple sclerosis: evidence from EEG event-related desynchronization.

Leocani L, Rovaris M, Martinelli-Boneschi F, Annovazzi P, Filippi M, Colombo B, Martinelli V, Comi G.

Clin Neurophysiol. 2005 Jul;116(7):1515-9. Epub 2005 Apr 26.

PMID:
15953556
39.

Visual evoked potentials may be recorded simultaneously with fMRI scanning: A validation study.

Comi E, Annovazzi P, Silva AM, Cursi M, Blasi V, Cadioli M, Inuggi A, Falini A, Comi G, Leocani L.

Hum Brain Mapp. 2005 Apr;24(4):291-8.

PMID:
15678479
40.

Cortical function abnormalities in migraine: neurophysiological and neuropsychological evidence from reaction times and event-related potentials to the Stroop test.

Annovazzi P, Colombo B, Bernasconi L, Schiatti E, Comi G, Leocani L.

Neurol Sci. 2004 Oct;25 Suppl 3:S285-7.

PMID:
15549563
41.

Therapy of primary headaches: the role of antidepressants.

Colombo B, Annovazzi PO, Comi G.

Neurol Sci. 2004 Oct;25 Suppl 3:S171-5. Review.

PMID:
15549531
42.

Neuropathic cranial pain.

Colombo B, Annovazzi PO, Comi G.

Neurol Sci. 2003 May;24 Suppl 2:S132-7. Review.

PMID:
12811612

Supplemental Content

Loading ...
Support Center